Berry Consultants employs world renowned experts in Bayesian statistics and clinical trial strategy, and strives to set the standard for innovative clinical trial design, analysis, and implementation. Meet our growing team.
Donald Berry is Founder of Berry Consultants, LLC, and a professor in the Department of Biostatistics of the University of Texas M.D. Anderson Cancer Center. He was founding Chair of this department in 1999. Dr. Berry received his Ph.D. in statistics from Yale University, and previously served on the faculty at the University of Minnesota and at Duke University. He has held endowed faculty positions at Duke University and M.D. Anderson.
Dr. Berry is a well known developer of statistical theory and methodology. He has designed and supervised the conduct of hundreds of innovative clinical trials, including Bayesian adaptive trials in cancer and other diseases. He has developed Bayesian adaptive designs that efficiently use information that accrues over the course of the trial. These trials minimize sample size while increasing the likelihood of detecting therapeutic activity. A principal focus of his research is the use of biomarkers for learning which patients benefit from which therapies, based on molecular markers and phenotype. In particular, he designed and is a co-PI of I-SPY 2 in high-risk early breast cancer, a trial that was the focus of the two lead articles with two editorials in the July 2016 NEJM. He has designed Phase 3 Bayesian adaptive platform clinical trials in glioblastoma, GBM-AGILE and pancreatic cancer.
Scott Berry is President and a Senior Statistical Scientist at Berry Consultants. He earned his MS and PhD in statistics from Carnegie Mellon University and was an Assistant Professor at Texas A&M University before co-founding Berry Consultants in 2000. He has led Berry Consultants to be widely regarded as the premier Bayesian consulting company in the world. Since 2000, he has been involved in the design of hundreds of Bayesian adaptive clinical trials of pharmaceuticals and medical devices and has become an opinion leader in the field of Bayesian adaptive clinical trials. Some of these trials have been groundbreaking trial designs, setting new standards for innovation and flexibility in trial design. These include the trials supporting the first fully Bayesian approval by the center for drug evaluation of the United States FDA (Pravastatin-Aspirin combination) and the statistical design for Time Magazine’s #2 Medical Breakthrough of 2007 (Veridex’s GeneSearch BLN Assay).
Cora Allen-Savietta is a Statistical Scientist at Berry Consultants. She specializes in designing innovative clinical trials with adaptive sample sizes, complex primary endpoints, and flexible platform structures. She works in various medical areas, including maternal health, heart failure, and progressive neurodegenerative diseases such as Parkinson’s and Alzheimer’s. She’s passionate about using a Bayesian framework to incorporate previous knowledge into future trial designs. For example, she’s used natural history data to simulate realistic control patients from a disease progression model and designed a phase III trial for a new cancer treatment with dynamic borrowing of the treatment effect across different tumor types. Cora is experienced in guiding statistical discussions and supporting clinical teams through conversations with regulators. While fluent in statistical theory, she ensures that clarity is not lost in the technical detail and enjoys distilling complex ideas into clear visuals and summaries. Before joining Berry Consultants, Cora earned a Ph.D. in Statistics from the University of Wisconsin, where she developed statistical methods for phylogenetics, epidemiology, and public health. Prior to graduate school, she worked at Harvard Medical School, studying medication safety and efficacy during pregnancy.
Lindsay Berry is a Statistical Scientist at Berry Consultants specializing in the design of Bayesian and adaptive clinical trials. She serves as an elected officer of the Section on Biostatistics and Pharmaceutical Statistics for the International Society for Bayesian Analysis (ISBA). She earned her PhD in Statistical Science from Duke University. During the COVID-19 pandemic, Dr. Berry was heavily involved in the design of Bayesian adaptive platform trials, leading to publication of actionable findings in the Journal of the American Medical Association and the New England Journal of Medicine. Dr. Berry’s interests focus on innovative Bayesian methods for clinical trials including adaptive allocation procedures, historical borrowing, evaluation of heterogeneity of treatment effect, and disease progression modeling.
Nick Berry is a Statistical Scientist at Berry Consultants. He specializes in the design and implementation of platform trials and other trials that require complex models for integrating disease-specific needs. He has worked on the design side of I-Spy 2, GBM AGILE, PRINCIPLE, Precision Promise, and other platform trials, as well as on the statistical analysis side implementing the I-Spy 2, PRINCIPLE, and PANORAMIC platform trials. He is also a developer for FACTS, especially the platform trial engine ─ this opportunity satisfies his passion for diving deep into complex coding problems. After receiving a B.S. in Applied Math at Texas A&M University, he completed an M.S. and a Ph.D. in Statistics at Iowa State University.
Anna L. Bosse is a Biostatistician at Berry Consultants. She earned her M.S. in Biostatistics from Virginia Commonwealth University School of Medicine (2017) and her B.S. in Mathematical Statistics from Loyola University Maryland (2015). Her master’s thesis compared variance estimators used when assessing the difference between correlated AUCs with finite samples. Prior to joining Berry Consultants, she was a Biostatistician at Statistics Collaborative, Inc. (SCI) in Washington, D.C. While at SCI, she worked with clinical trials evaluating treatments in a range of therapeutic areas, including oncology, hematology, ophthalmology, psychiatric disorders, and infectious, renal and respiratory diseases. She assisted in the preparation of safety and efficacy reports for Data Monitoring Committees (DMCs), performing statistical analyses, programming analysis datasets, generating table, listing and figure presentations, and validating SAS program code.
Amy M. Crawford is a Statistical Scientist at Berry Consultants. She earned her Ph.D. in Statistics from Iowa State University in 2020. Her doctoral research focused on developing Bayesian hierarchical models for identifying the writer of handwritten documents at the NIST Forensic Science Center of Excellence. During her time in Iowa, she also worked on developing statistical learning methods for problems with dataset shift and missingness by a known mechanism with applications in credit card fraud detection. Amy earned her B.S. in Mathematics and Statistics from North Dakota State University.
Michelle A. Detry is a Director, Adaptive Trial Execution & Senior Statistical Scientist for Berry Consultants with expertise in Phase I, II, and III clinical trial design and analysis/reporting in support of Data Monitoring Committees (DMCs). She received her PhD in Biometry in 2003 from the University of Texas-Houston School of Public Health. Prior to joining Berry Consultants in 2011, Dr. Detry was an Assistant Scientist in the Department of Biostatistics & Medical Informatics in the University of Wisconsin School of Medicine and Public Health. In that role, she led projects focused on the design and creation of reports prepared for independent DMCs for multicenter Phase II/III and Phase III industry sponsored clinical trials, frequently taught seminars on study design and statistical methods to postdoctoral clinical fellows, and co-developed the workshop series “Clinical Research Study Design”. Prior to her position at the University of Wisconsin, Michelle was a Principal Statistical Analyst at the University of Texas M. D. Anderson Cancer where she designed clinical trials using Bayesian methods. In addition to clinical trials, Dr. Detry has experience in the analysis of data for healthcare quality improvement, epidemiology, and basic science research.
Mark Fitzgerald joined Berry Consultants as a Statistical Scientist in 2013. He earned his PhD in statistics from Carnegie Mellon University in 1996, and has since worked at Los Alamos National Laboratory, University of Colorado at Denver, and Neptune and Company. He has broad experience with statistical and mathematical modeling in a wide range of scientific disciplines. He especially enjoys collaborating with other researchers, which has led to work in a variety of fields, including medicine, functional magnetic resonance imaging, physics, chemistry, ecology, manufacturing, and environmental science. His research efforts emphasize stochastic simulation, Bayesian analysis, decision analysis, and expert elicitation. He has contributed to papers across disciplines with his many collaborators, as well as serving as Associate Editor for the Journal of Computational and Graphical Statistics.
Todd Graves joined Berry Consultants as a Statistical Scientist in January 2012 and focuses his work on the design of adaptive clinical trials for a variety of clients. For twelve years he was a member of the Statistical Sciences group at Los Alamos National Laboratory. At Los Alamos he specialized in statistical computation, Bayesian data analysis, and reliability problems, especially combining multiple sources of information. He and his coauthors won the American Society for Quality’s 2007 Frank Wilcoxon Prize. He was a Postdoctoral Fellow of the National Institute of Statistical Sciences from 1995 through 1999 after receiving his Ph.D. in Statistics from Stanford University in 1995. He has served as Associate Editor for the Journal of Computational and Graphical Statistics.
Peter Jacko is a Senior Decision Scientist for Berry Consultants. He earned his Ph.D. in Business Administration and Quantitative Methods and D.E.A. in Statistics and Operations Research from the Universidad Carlos III de Madrid, Spain, and received his Mgr. and Bc. degrees in Mathematics from the Univerzita P.J. Šafárika v Košiciach, Slovakia. In addition to Berry Consultants, Dr. Jacko is a Senior Lecturer (Associate Professor) in the Department of Management Science at Lancaster University, UK which he joined in 2013. Between 2009 and 2018 he was affiliated with the BCAM – Basque Center for Applied Mathematics, Spain, where he was formerly a postdoctoral fellow, researcher, co-leader, and an external scientific member in the Networks research group.
Dr. Jacko is devoted to the development of the science of the solution of problems in the design and management of complex systems such as public health processes, business decision-making, and communications networks. Much of his research work benefits from the interaction of mathematics, statistics, computing, and/or economics. The leading themes of his research activities are stochastic modelling of real problems and the design of tractable and well-performing solutions for efficient allocation of scarce resources over time. Dr. Jacko has co-authored over 30 peer-reviewed publications which have contributed to the disciplines of operational research, statistics and computer science, especially in the methodological areas of stochastic modelling, performance evaluation, optimization, and reinforcement learning. His main research line recently has been on the optimal patient-centric design of modern adaptive clinical trials, which can often be modelled as variants of the Bayesian multi-armed bandit problems.
Michael Jackson is a Software Engineer for Berry Consultants. He has over thirty years of experience in software design, architecture and development. Prior to joining Berry Consultants, he worked at The University of Texas at Austin in the Petroleum Engineering and Geoservices Department as a Senior Software Developer/Analyst in the research group. For ten years prior to UT, Michael worked as an independent consultant, providing software and IT services to multiple industries. Early in his career, Michael co-owned and managed one of the largest home care provider agencies in Texas and focused his efforts on the company’s software and IT infrastructure.
Nathan T. James is a Statistical Scientist at Berry Consultants. He has previous experience as a public health data analyst, an academic research associate, and a CRO biostatistician. He earned a Ph.D. in Biostatistics from Vanderbilt University, where his doctoral research focused on semi-parametric Bayesian cumulative probability models and Bayesian variational inference for population pharmacokinetic models using real-world evidence. He also completed an FDA ORISE Fellowship to explore Bayesian copula modeling and semi-parametric regression for clinical trials. At Berry, he has adeptly translated clinical research questions into statistical modeling while designing early phase and pivotal trials for cardiovascular, neurodegenerative, and genetic diseases, among other areas. He is passionate about answering complex scientific questions using innovative statistical methodology.
Tom Jensen is a Biostatistician at Berry Consultants. He earned his M.S. in Statistics from Brigham Young University in 2021. While completing his B.S. in Statistics at Brigham Young University, he collaborated with psychologists to implement cognition trials and analyze EEG data output. His Master’s project topic was Bayesian random partition models and cluster analysis. His other research interests include disease progression modeling, Bayesian hierarchical modeling, reliability analysis, and statistical computing.
Farah Khandwala is a Statistical Scientist for Berry Consultants, where she primarily works on the implementation team and is involved in the preparation and execution of interim and final analyses, DSMB communication, CSR/manuscript reporting, and documentation for regulatory submissions. Early in her career, she designed studies in various therapeutic areas at the Department of Quantitative Health Sciences, Cleveland Clinic Foundation, before moving on to Cancer Epidemiology and Prevention at Alberta Health Services. Prior to joining Berry, she worked in the CRO industry, overseeing the leadership of CDISC compliant trials across all phases. Integrating her academic background and CRO experience, she brings scientific rigor and validation best practices to the Berry team. Farah earned her M.S. in Statistics from Simon Fraser University in 2001, with a specialization in statistical computing and Bayesian methods.
Roger J. Lewis, MD, PhD, is the Senior Medical Scientist for Berry Consultants. He received his PhD in Biophysics in 1986 and his MD in 1987 from Stanford University. He completed clinical training in emergency medicine in 1990 and is currently a Professor at the David Geffen School of Medicine at UCLA and an attending physician in the Department of Emergency Medicine at Harbor-UCLA Medical Center. Dr. Lewis’s areas of interest include adaptive and Bayesian clinical trials; platform trials; translational, clinical, health services and outcomes research; the role and function of data monitoring committees; and difficulties surrounding informed consent in emergency research studies. Dr. Lewis has served as a research mentor for numerous fellows and junior faculty and frequently lectures on the topics of clinical research design and the statistical analysis of clinical trials. READ MORE
Elizabeth Lorenzi is a Statistical Scientist for Berry Consultants. She earned her Ph.D. in Statistical Science from Duke University in May 2019. Her research focused on developing machine learning and causal inference methods for precision medicine applications. While at Duke, she collaborated on multiple research projects focusing on the following clinical problems: predicting risk of complications after surgery, assessing the effectiveness of pre-operative clinics and pre-operative calculators as methods to reduce the risk of complication after surgery, and deciding treatment decisions for Type 2 Diabetes patients from electronic health record data. Prior to her time at Duke, she completed a Masters in Statistical Science and a Bachelor of Science in Statistics and Economics from Carnegie Mellon University.
Pravin Madhavan is a Senior Software Engineer for Berry Consultants, where he is responsible for the development of the UI components of FACTS (Fixed and Adaptive Clinical Trial Simulator). He earned his Ph.D and B.Sc. in Mathematics from the University of Warwick and his M.Sc. in Mathematical Modelling and Scientific Computing from the University of Oxford. His Ph.D. research focused on developing and implementing efficient computational methods for partial differential equations on complex surfaces. He has authored several papers in high impact peer reviewed journals within this field. Prior to joining Berry Consultants, he was an analyst programmer at Tessella Ltd. (an international data science, analytics and AI technology consulting services provider) and a full-stack software developer at Enable International Ltd (a software product development and trading partner collaboration solutions provider).
Joe Marion is a Senior Statistical Scientist for Berry Consultants, where he specializes in designing Bayesian and adaptive clinical trials in a broad range of disease areas. Joe is particularly passionate about clinical trials in rare pediatric diseases. These heterogeneous diseases offer opportunities to create customized, disease-specific analyses that are more precise and powerful than traditional approaches. He also has substantial experience with platform trials and has been involved in the design and implementation of platform trials in diseases areas including oncology, neurology, and psychiatric disorders. Joe is interested in the technical and methodological side of statistics and brings a mathematical perspective to understanding and evaluating clinical trials. Joe earned his Ph.D. in Statistics from Duke University in 2018. His research focused on computational methods for Bayesian inference, developing theoretical guarantees for sequential Monte Carlo estimators and adaptive path selection methods for thermodynamic integration. Prior to graduate school, he served as a Field Artillery Officer in the US Army.
Anna McGlothlin is a Director and Senior Statistical Scientist for Berry Consultants. She earned her Ph.D. in Statistics from Baylor University, with research focused on Bayesian methodology and measurement error. Prior to joining Berry Consultants, she was a Senior Research Scientist in the early phase oncology group at Eli Lilly and Company. While at Lily, she was frequently sought out by colleagues for consultation on clinical trial design, especially adaptive design.
William Meurer, M.D, M.S. is an Associate Professor of Emergency Medicine and Neurology at the University of Michigan Health System. In addition, he serves as a Medical & Statistical Scientist for Berry Consultants. He works to improve the care of patients with acute neurological disease both through his work on the acute stroke team and as a researcher. His work in the field focuses on the design of clinical trials with adaptive and flexible components. In addition, he is a principal investigator of the National Institutes of Neurological Disorders and Stroke (NINDS) Clinical Trials Methodology Course (http://neurotrials.training) and a co-investigator in the clinical coordinating center of the Strategies to Innovate Emergency Clinical Care Trials (SIREN) network – also funded by NIH). He is principal investigator of NIH funded trials that include an ED based text messaging intervention for hypertension and a cluster randomized trial to improve the care of patients with acute dizziness. He was a co-investigator on the Adaptive Designs Accelerating Promising Treatments into Trials (ADAPT-IT) project, as part of the FDA Advancing Regulatory Science initiative with NIH.
He attended college at the Ohio State University, medical school at the University of Cincinnati, residency at MetroHealth/Cleveland Clinic and then came to Michigan for his stroke fellowship in 2006. During that fellowship he received an M.S. in clinical research design and statistical analysis from the University of Michigan School of Public Health. He has authored over 80 original publications (65 original scientific papers) – journals represented include JAMA. He is a core-faculty member for the University of Michigan/St. Joseph Mercy Residency. In addition, he serves clinically both the in the Emergency Department and with the University of Michigan Stroke Team.
Elias Laurin Meyer is a Statistical Scientist at Berry Consultants based in Vienna, Austria. Prior to joining Berry Consultants, he worked for several years at the Medical University of Vienna, where he (co-)authored around 40 peer-reviewed publications and where his tasks and interests ranged from statistical consulting, data analysis and drafting study protocols to teaching, methodological research and statistical programming. He has gained industry experience while on secondments at Roche and Novartis and had the opportunity to participate in regulatory interactions through FDA CPIM and EMA ITF meetings related to the design and simulation of a platform trial in NASH. Prior to earning his Ph.D. in 2022 while working on the EU-PEARL project, he received a BSc and MSc in Statistics from the University of Vienna and worked as an EMT and ambulance driver. Finally, Dr. Meyer is an expert biostatistics reviewer for the Viennese Ethics Committee (IRB).
Jessica Overbey is a Statistical Scientist at Berry Consultants. She earned her MS and DrPH in Biostatistics from Columbia University. Her doctoral research focused on statistical issues related to shared control groups in platform trials. Prior to joining Berry Consultants, Dr. Overbey was an Assistant Professor of Biostatistics at the Icahn School of Medicine at Mount Sinai. She has authored over 70 peer-reviewed publications and has extensive experience in the design, implementation and analysis of clinical trials across a wide range of therapeutic areas including cardiothoracic surgery, neurology, psychiatry, obstetrics, and rare genetic disorders.
Tom Parke is Director of Software Solutions for Berry Consultants. Tom’s passion and experience has been software for adaptive clinical trials. Prior to joining Berry Consultants, he was Head of Clinical Trial Solutions for Tessella Ltd. While at Tessella for nearly 20 years, he managed the development and running of the software system to support Pfizer’s ASTIN Stroke trial, and has setup multiple software systems to support different aspects of many adaptive clinical trials, mostly designed by Berry Consultants. In parallel, he managed projects to develop clinical trial simulators, first with Pfizer, then Wyeth, before acting as the expert advisor and reviewer to the joint development of FACTS with Berry Consultants. Prior to working at Tessella, he worked for Inmos, Imperial Software Technology, and Praxis on compilers, operating systems and real time control systems. He graduated with a Joint First Class Honours in Math and Computer Science from Bristol University in 1979.
Melanie Quintana is a Director and Senior Statistical Scientist at Berry Consultants, where she specializes in designing Bayesian adaptive clinical trials across a wide range of therapeutic areas. Her work includes numerous examples in designing platform trials and clinical trials in rare and progressive disease with a focus on developing models of disease progression to design better and more powerful clinical trials. Before joining Berry Consultants, she earned her Ph.D. in Statistics from Duke University and went on to pursue a Postdoc in Biostatistics at The University of Southern California. While at Duke and USC, she worked closely with collaborators within multiple large studies and consortiums around the nation to develop and implement analytical strategies to assess genetic risk factors for various complex diseases. These collaborations sparked and continue to fuel her interests in developing Bayesian approaches for complex clinical questions.
Christina T. Saunders is a Statistical Scientist at Berry Consultants. She serves on the unblinded team of statisticians who conduct efficacy analyses for Bayesian adaptive trials. She has contributed to the platform trials REMAP-CAP, PRINCIPLE, GBM AGILE, and PANORAMIC, and the combined master protocol for the REMAP-CAP, ACTIV-4a, and ATTACC trials. She has conducted over 100 trial updates/final analyses for platform trials and has helped implement adaptive trials in various therapeutic areas, including oncology, Alzheimer’s disease, COVID-19, nephrology, stroke, and digestive disorders. Christina is a co-author on peer-reviewed publications in NEJM, JAMA, and The Lancet. She has taught short courses at conferences and for industry clients, sharing her expertise in adaptive/platform trial implementation and DSMB statistical reporting. She holds a B.S. in mathematics from Baylor University and a Ph.D. in biostatistics from Vanderbilt University, where she collaborated with investigators in the Center for Kidney Disease and the Department of Thoracic Surgery. Her doctoral research focused on methods in mediation analysis and causal inference. As a member of the implementation team for adaptive trials at Berry Consultants, Christina endeavors to support scientific rigor, protect trial integrity, and contribute to evidence-based conclusions that may improve patient care.
Juliana Tolles, M.D, M.H.S. is a Medical and Statistical Scientist for Berry Consultants. She is an Assistant Professor of Emergency Medicine at the David Geffen School of Medicine at UCLA and a core faculty member for the Harbor-UCLA Emergency Medicine residency program. Her academic research interests include emergency medical services, resuscitation medicine and trauma care. She has authored several reviews for JAMA on statistical methodology and has lectured nationally on research methodology for the Society for Academic Emergency Medicine Advanced Research Methodology Evaluation and Design (ARMED) course. She is also a co-investigator for the Strategies to Innovate Emergency Clinical Care Trials (SIREN) network Southern California site.
Dr. Tolles attended college at Harvard University and medical school at Yale University School of Medicine, where she also received a Master of Health Sciences and completed a Doris Duke Fellowship in clinical research. She completed both her residency in emergency medicine and research fellowship at Harbor-UCLA Medical Center in Los Angeles.
Matteo Vestrucci is a Statistical Scientist at Berry Consultants.
Based in Austin, Texas, he started working in conjunction with the
company while completing his Ph.D. in Statistics at the University of Texas at Austin, then joined Berry Consultants when he graduated in 2021. Prior to his doctoral work, Matteo received a B.S. and M.S. in Statistics from the University of Milano-Bicocca in Italy and accumulated industry experience while working on the DIAN-TU Alzheimer’s disease clinical trial for Roche. His activities at Berry Consultants encompass many types of advanced Bayesian trials, ranging from Goldilocks designs to platform trials such as the Healey ALS platform trial; and trial design work ranging from constructing disease progression models to harnessing historical data in order to borrow information dynamically, or to power trials. He has a good intuition for designing complex models through his attention to precise details and enjoys solving computational challenges through efficient custom coding. He has had the opportunity to participate in regulatory interactions, in particular with the FDA and its CID program.
Kert Viele is a Director and Senior Statistical Scientist with Berry Consultants, where he leads Berry Consultants’ research enterprise. He is a leader in clinical trial implementation of Bayesian hierarchical modeling, with expertise in platform and basket trials as well as clinical trials incorporating the use of historical information. Prior to joining Berry Consultants in 2010, he was a faculty member at the University of Kentucky, where he received the Provost’s Award for Outstanding Teaching and was an investigator for NSF and NIH funded research. He has developed over 100 custom Bayesian adaptive clinical trials for clients in industry, government, and academia, and currently serves on several data safety monitoring boards for randomized clinical trials. A former editor of the journal Bayesian Analysis, Dr. Viele is also an author of FACTS (Fixed and Adaptive Clinical Trial Simulator), clinical trial simulation software currently licensed to multiple pharmaceutical, academic, and government organizations.
Barbara Wendelberger is a Senior Statistical Scientist at Berry Consultants, where she focuses on innovative statistical approaches to address complex challenges in clinical trial design. She designs Bayesian adaptive clinical trials for numerous therapeutic areas and specializes in leveraging natural history data on biomarkers and clinical endpoints to model disease progression. Barbara is passionate about translating a deeper biological understanding of a disease to a more efficient and informative clinical trial, particularly in neurodegenerative and rare diseases. Before joining Berry Consultants in 2016, she earned her PhD from the University of Wisconsin. Her doctoral research focused on a Variational Bayesian method for estimating neural effective connectivity networks using information from multiple imaging modalities. Previously, Barbara was a member of the Genomics group at Los Alamos National Laboratory, participating in both sequencing technology and metagenomics research. Her research interests continue to focus on data-driven inference at the juncture between statistics, mathematics, biology, and medicine.
Philip White is a Statistical Scientist for Berry Consultants. Before joining Berry Consultants, he was a faculty member in the Department of Statistics at Brigham Young University. His expertise includes hierarchical modeling, Bayesian statistics, and Bayesian non- and semi-parametric methods for the analysis of time series, functional, and spatial data. He has co-authored over 20 peer-reviewed articles in the statistical and scientific literature. He and his co-authors won the Wiley-TIES Best Environmetrics Paper Award in 2019. His previous consulting includes work in studying ecology, social dynamics, human-animal interactions, veterinary science, animal behavior, early-stage product development, and marketing. After receiving a B.S. in Applied Physics and M.S. in Statistics from Brigham Young University, he earned his Ph.D. in Statistical Science from Duke University in 2019.
Shawn Andersson is Vice President, Finance & Operations for Berry Consultants. Shawn is responsible for overseeing business operations, strategic planning and analysis, finance, human resources, contract management, and compliance for Berry Consultants. He earned his Bachelor of Business Administration in Finance from Texas A&M University and Master of Business Administration from The University of Texas at Dallas. Prior to joining Berry Consultants in 2012, he held similar operational roles for 15 years within the semiconductor industry and higher education.
Henrik Schmiediche is the Senior IT Manager for Berry Consultants. Henrik was formerly the Director of IT at the College of Science at Texas A&M University where he directed the computing operations in support of faculty, staff, and students. In prior years he was the IT manager at the Dept. of Statistics at Texas A&M supporting Statistics professors and graduate students with their computing needs. He has worked as a Linux systems administrator and a HPC systems engineer managing a 300+ node cluster with a high-speed network fabric and large parallel file storage. Henrik has experience in SQL, FORTRAN, C++, C# and .NET software development and AWS and Azure cloud computing. At Texas A&M he created and taught a popular course for graduate students on Databases and Computational Tools used in Big Data. He currently maintains the computational and networking environment at Berry Consultants. Henrik earned his M.S. and Ph.D. in Statistics from Texas A&M with an emphasis on statistical graphics.
Misty Vasquez is the Operations Manager for Berry Consultants. Misty joined Berry Consultants in December 2007 and handles the overall accounting, client invoicing, accounts receivable, accounts payable, and payroll for Berry Consultants. Prior to joining Berry Consultants, she worked for Texas A&M University for 17 years. Her last position there was in the Dean’s Office of the College of Engineering where she supported the advising and recruiting programs. She also was the coordinator of the College of Agriculture and Life Sciences scholarship program for 10+ years.
Daniel Jimenez is a Project Manager for Berry Consultants, where he is responsible for the Data Warehouse, ensuring flawless data migration, enabling analysis and reporting, and supporting the overall growth and success of the organization. Daniel is a Certified Associate in Project Management (CAPM) with experience in data analytics and database management. He earned his B.S. in Information Technology from Texas Tech University in 2020 with a concentration in Data Analytics. Before joining Berry Consultants, Daniel worked as an IT Project Manager for NASA, assisting with two space projects. Prior to that, he worked for three years as a research assistant for Texas Tech University supporting research, teaching, and IT service projects.
Doray Sitko is a Director of Project Management for Berry Consultants, where she is responsible for managing new project requests, tracking existing projects, coordinating resource availability, providing project management leadership, and supporting the overall growth and success of the organization. Doray is a certified Project Management Professional (PMP) with experience in health care, education, research, and business development. She holds a Master’s of Science degree in Health Education from Virginia Tech and a Bachelor’s of Health Science degree from Towson University. Since 2007, Doray has provided professional and project management services in the consulting industry, including 12 years supporting work funded primarily by US federal government agencies.